Every 8-K that Abbott Labs (ABT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ABT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ABT filings page.
Abbott Laboratories (ABT) reported that it has entered into settlement agreements resolving the Missouri Gill case and necrotizing enterocolitis (NEC) claims involving approximately 2,000 additional infants relating to its specialty formulas for preterm infants. The aggregate settlement amount is approximately $670 million, described as a compromise of disputed claims and not an admission of liability.
The company had faced a $495 million jury verdict in the Gill case, which, with accrued interest, would have required payment of about $600 million absent further appeals or settlement. Abbott states it believes the agreements are in its long‑term interest and a constructive step toward substantially resolving the overall litigation. After these agreements, about 1,700 lawsuits remain pending involving claims on behalf of roughly 12,700 infants.
Abbott Laboratories reported strong top-line growth for the quarter ended June 30, 2026. Net sales were $12.593 billion, up 13.0% year over year, with comparable sales growth of 4.8%. GAAP diluted EPS was $0.53 versus $1.01 a year ago, while adjusted diluted EPS, which excludes $1.362 billion of specified after-tax charges including $658 million of intangible amortization and acquisition- and legal-related costs, rose to $1.31 from $1.26.
Diagnostics and Medical Devices led performance, with comparable sales growth of 2.9% and 8.4% respectively, while Established Pharmaceuticals grew 8.7% and Nutrition declined 3.6% on a comparable basis. Abbott completed the acquisition of Exact Sciences, advancing its Cancer Diagnostics business, and highlighted progress in key pipeline programs, including completion of enrollment in the TECTONIC trial, CE Mark for the Libre Duo glucose‑ketone sensor, and FDA submission for the Amulet 360 device.
Management reaffirmed full‑year 2026 comparable sales growth guidance of 6.5%–7.5% and raised full‑year adjusted EPS guidance to $5.45–$5.60, with third‑quarter adjusted EPS projected at $1.38–$1.46. The company returned $2.1 billion to shareholders in the quarter and declared its 410th consecutive quarterly dividend of $0.63 per share.
Abbott Laboratories reported that shareholders approved its new 2026 Incentive Stock Program, authorizing up to 140,000,000 common shares for equity-based awards. The plan lets the company grant stock options, restricted stock, restricted stock units, performance awards and other share-based incentives to employees and non-employee directors.
Kevin Conroy was named to Abbott’s Board of Directors, and the board size was increased from twelve to thirteen members effective April 24, 2026. Shareholders also elected the director slate and approved routine governance matters at the annual meeting.
Abbott Laboratories reported first-quarter 2026 results that met its internal expectations and highlighted a major expansion into oncology diagnostics. Net sales were $11.164 billion, up 7.8% year over year, with comparable sales growth of 3.7% after adjusting for foreign exchange, the Exact Sciences acquisition and a structural heart agreement.
GAAP net earnings were $1.077 billion and diluted EPS was $0.61, both down about 19% from a year ago, driven by higher operating costs and acquisition-related charges. Excluding specified items, adjusted net earnings rose to $2.022 billion, and adjusted diluted EPS increased 6% to $1.15.
Medical Devices led growth with reported sales up 13.2%, while Diagnostics rose 6.1% and Established Pharmaceuticals 13.2%; Nutrition declined 6.0% as Abbott reset pricing and volumes. On March 23, 2026, Abbott completed its acquisition of Exact Sciences, creating a new Cancer Diagnostics business built around Cologuard and the Cancerguard multi-cancer screening test.
Abbott now projects full-year 2026 comparable sales growth of 6.5%–7.5% and adjusted diluted EPS of $5.38–$5.58, including $0.20 of dilution from the Exact Sciences deal. It also guided second‑quarter 2026 adjusted diluted EPS to $1.25–$1.31 and declared its 409th consecutive quarterly dividend of $0.63 per share.
Abbott Laboratories has completed its acquisition of Exact Sciences, making Exact a wholly owned subsidiary focused on cancer screening and diagnostics. Each Exact Sciences common share was converted into the right to receive $105.00 in cash at closing. Exact’s last trading day on Nasdaq was March 20, 2026. The deal adds leading products such as Cologuard, Oncotype DX, Oncodetect and Cancerguard, and expands Abbott’s presence in U.S. cancer screening and precision oncology diagnostics, which the company cites as a $60 billion market.
Abbott Laboratories completed a major debt financing, issuing $20 billion of senior notes in multiple tranches maturing between 2029 and 2066, including fixed-rate coupons from 3.700% to 5.600% and a floating-rate 2029 series.
Abbott plans to use the net proceeds, along with cash and possible additional borrowings, to fund the acquisition of Exact Sciences Corporation, repay Exact Sciences’ debt, cover related fees and expenses, and for general corporate purposes such as debt repayment. If the Exact Sciences acquisition is not completed by a deadline tied to the merger agreement’s End Date, or Abbott abandons the deal, Abbott must redeem all outstanding notes at 101% of principal plus accrued interest under a special mandatory redemption feature.
Abbott Laboratories entered into a pricing agreement to issue and sell $20,000,000,000 aggregate principal amount of senior notes across eight tranches, including Floating Rate Notes due 2029 and Fixed Rate Notes with coupons from 3.700% to 5.600% maturing between 2029 and 2066.
The notes were priced through a syndicate led by major underwriters and offered under Abbott’s effective shelf registration statement via a prospectus and prospectus supplement. Closing of the notes offering is expected on March 9, 2026, subject to customary conditions.
Abbott plans to use the net proceeds, together with cash on hand and/or additional borrowings, to fund consideration for its proposed acquisition of Exact Sciences Corporation, repay certain Exact Sciences indebtedness, cover related fees and expenses, and for general corporate purposes, which may include repayment of other debt.
Abbott Laboratories is updating its corporate governance by changing the size of its Board of Directors. Effective April 24, 2026, the board will be reduced from thirteen directors to twelve, as reflected in an amendment to Article III, Section 2 of Abbott’s By-Laws.
The company has restated its By-Laws to incorporate this change, and the amended and restated By-Laws will be effective on the same date. No financial results or major transactions are included in this report; it focuses solely on this board size adjustment.
Abbott Laboratories filed a current report to note that it announced its results of operations for the fourth quarter and full year 2025 on January 22, 2026. The detailed financial results are provided in a separate news release furnished as Exhibit 99.1.
Abbott explains that the news release uses several non-GAAP financial measures, including net earnings excluding specified items. These measures adjust for items such as acquisition and restructuring expenses, legal reserves, fair value changes in contingent consideration, certain regulatory costs, various tax-related items, and excess tax benefits from share-based compensation. The measures also exclude intangible amortization expense so management can assess performance without these costs.
Management believes these non-GAAP measures give investors additional insight into ongoing business performance and uses them internally to monitor the business, while cautioning that they should be considered alongside, and not as a replacement for, GAAP metrics.
Abbott Laboratories filed a Form 8-K announcing a governance update. On December 12, 2025, Nita Ahuja, M.D. was named to Abbott’s Board of Directors. On the same date, Abbott’s Board amended the first sentence of Article III, Section 2 of its by-laws so that the Board shall consist of thirteen directors, an increase from twelve, effective December 12, 2025. Abbott also filed its amended and restated by-laws as an exhibit, reflecting these changes.
Abbott Laboratories reported that its U.S. and Puerto Rico stock retirement plans will undergo an administrative blackout period. The blackout is being implemented to make several plan administration changes, including switching the recordkeeper, changing the trustee for certain U.S. Plan funds, and changing the custodian for certain P.R. Plan funds.
During the blackout, participants in these plans will not be able to change contribution rates, reallocate or diversify investments (including Abbott common shares), or obtain loans, withdrawals, or distributions from their plan accounts. The blackout is expected to begin on December 24, 2025 at 12 p.m. CST and to end during the week of January 11, 2026.
Abbott also notified its directors and executive officers about the blackout and related restrictions on trading in Abbott common shares under Section 306 of the Sarbanes-Oxley Act and Regulation BTR. Additional information about the blackout, including its actual start and end dates, is available on request from Abbott for two years after it ends.
Abbott Laboratories announced a definitive agreement to acquire Exact Sciences through a cash merger. Each outstanding Exact Sciences common share will be converted at closing into the right to receive $105.00 in cash, subject to customary terms and tax withholding, with Exact Sciences becoming a wholly owned Abbott subsidiary.
The deal is conditioned on approval by holders of at least a majority of Exact Sciences shares, required regulatory clearances including expiration or termination of the Hart-Scott-Rodino waiting period, absence of legal restraints, and satisfaction of representations, covenants, and a no–material adverse effect condition on Exact Sciences. In connection with signing, Abbott obtained a commitment for up to $20,000,000,000 of senior unsecured bridge loans to support the transaction.
Abbott Laboratories reported its third-quarter 2025 results, noting that the information was furnished under Item 2.02 and accompanied by a press release as Exhibit 99.1.
The company highlighted the use of non-GAAP financial measures to evaluate ongoing business performance. These measures adjust for items that can be unusual or unpredictable, including acquisition-related expenses, restructuring actions, fair value changes in contingent consideration, certain regulatory costs, adjustments tied to prior recognition of a significant non-cash deferred tax benefit, tax benefits associated with specified items, net tax benefit from resolution of prior-year tax positions, and excess tax benefits from share-based compensation. They also exclude intangible amortization expense to show results excluding these costs. Management believes these metrics provide useful insight for investors, while cautioning they should be considered alongside GAAP results.